Market Currents
Edwards Lifesciences (EW +5.4%) shares surge to the top of the S&P after a study shows...
-
Tuesday, January 31, 2012, 9:49 AM ETEdwards Lifesciences (EW +5.4%) shares surge to the top of the S&P after a study shows elderly patients receiving its Sapien heart valve implanted through the ribs as part of an expanded access program reaped more benefit than those observed in initial trials. Cannacord, which rates shares a Buy, thinks the data will ease FDA concerns, and raises its target price to $95 from $90.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
